Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

Study Questions:

What is the efficacy and safety of rivaroxaban administered for 35 days, as compared with enoxaparin administered for 10 days and followed by placebo, among hospitalized patients 40 years of age or older with reduced mobility and acute medical illness?